Related Experiment Video
Updated: Sep 2, 2025
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities
Alcida Karz1,2, Maya Dimitrova2,3, Kevin Kleffman1,2
1Department of Pathology, NYU Grossman School of Medicine, New York, USA.
Abstract:
Brain metastases are the most common brain malignancy. This review discusses the studies presented at the third annual meeting of the Melanoma Research Foundation in the context of other recent reports on the biology and treatment of melanoma brain metastases (MBM). Although symptomatic MBM patients were historically excluded from immunotherapy trials, efforts from clinicians and patient advocates have resulted in more inclusive and even dedicated clinical trials for MBM patients. The results of checkpoint inhibitor trials were discussed in conversation with current standards of care for MBM patients, including steroids, radiotherapy, and targeted therapy. Advances in the basic scientific understanding of MBM, including the role of astrocytes and metabolic adaptations to the brain microenvironment, are exposing new vulnerabilities which could be exploited for therapeutic purposes. Technical advances including single-cell omics and multiplex imaging are expanding our understanding of the MBM ecosystem and its response to therapy. This unprecedented level of spatial and temporal resolution is expected to dramatically advance the field in the coming years and render novel treatment approaches that might improve MBM patient outcomes.
Insights
Melanoma brain metastases (MBM) are increasingly studied with inclusive immunotherapy trials. New research reveals MBM vulnerabilities and uses advanced imaging to improve patient outcomes.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Immunotherapy
Background:
- Brain metastases represent the most frequent intracranial malignancy.
- Melanoma brain metastases (MBM) historically faced exclusion from clinical trials, limiting treatment advancements.
- Recent progress has led to more inclusive trials for MBM patients.
Purpose of the Study:
- To review recent advancements in the biology and treatment of melanoma brain metastases (MBM).
- To discuss findings from the Melanoma Research Foundation's third annual meeting in the context of current literature.
- To explore emerging therapeutic strategies and research directions for MBM.
Main Methods:
- Review of studies presented at the Melanoma Research Foundation's third annual meeting.
- Synthesis of recent reports on MBM biology and treatment.
- Discussion of checkpoint inhibitor trial results alongside current standards of care (steroids, radiotherapy, targeted therapy).
Main Results:
- Increased inclusivity in immunotherapy trials for MBM patients, including dedicated trials.
- Emerging understanding of MBM biology, including the role of astrocytes and metabolic adaptations.
- Advancements in single-cell omics and multiplex imaging are enhancing the understanding of the MBM ecosystem and treatment responses.
Conclusions:
- Advances in understanding MBM biology and the tumor microenvironment are revealing new therapeutic targets.
- Technical innovations in omics and imaging are providing unprecedented resolution of the MBM ecosystem.
- These advancements are poised to drive novel treatment approaches and improve outcomes for MBM patients.
Related Concept Videos
02:56Treatment Resistant Cancers
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...